Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.

Stefano CascinuToshifumi TadaShigeo ShimoseTakashi KumadaTakashi NiizekiStefano CascinuAlessandro Cucchetti

Published in: Targeted oncology (2021)

The present MAIC highlights that the combination of atezolizumab plus bevacizumab is superior to lenvatinib. However, updated data or sub-analyses of the IMbrave150 trial would provide more robust estimates for such a treatment comparison.

Keyphrases

clinical trial
electronic health record
phase iii
squamous cell carcinoma
big data
replacement therapy
double blind